Today, we want to share our analysis of Exelixis (EXEL) with you. The company's stock price has declined by more than 9% since mid-July despite the absence of company-specific negative news. The company has a debt-free balance sheet, strong pipeline progress, and its lead drug continues to gain market share.
Company Description
Exelixis is a commercial biotechnology company developing treatments for cancer. The company, based in Alameda, CA, was founded in 1994 and went public in April 2000, selling 9.1M shares at $13.00 per share. Exelixis is led by Michael M. Morrissey who